# Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHD

> **NCT02652130** · PHASE3 · COMPLETED · sponsor: **Mesoblast, Inc.** · enrollment: 32 (actual)

## Conditions studied

- Grade B Acute Graft Versus Host Disease
- Grade C Acute Graft Versus Host Disease
- Grade D Acute Graft Versus Host Disease

## Interventions

- **BIOLOGICAL:** Remestemcel-L

## Key facts

- **NCT ID:** NCT02652130
- **Lead sponsor:** Mesoblast, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-28
- **Primary completion:** 2018-06-15
- **Final completion:** 2018-06-15
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2022-03-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02652130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02652130, "Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHD". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02652130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*